Reported 2 days ago
Jefferies has raised its price target for aTyr Pharma, Inc. (NASDAQ:ATYR) from $9 to $17, maintaining a Buy rating prior to the Phase 3 trial results of its lead candidate, efzofitimod. The results are expected in mid-September 2025, with Jefferies assessing a 37% chance of strong positive outcomes that could significantly boost the stock price. There is also a noted need for treatments in pulmonary sarcoidosis, which currently lacks approved therapies.
Source: YAHOO